Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, particularly related to misrepresentation of a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company misrepresented the nature of its partnership with Novo Nordisk, claiming it could sell both Wegovy and compounded semaglutide, and asserted compliance with FDA regulations [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, a decline of over 34%, from $64.22 to $41.98 per share [5].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) between April 29, 2025 and June 22, 2025, inclusive. Should You Join This Class Action Lawsuit? If you purchased or acquired Hims securities, and/or would like to discuss your legal rights and options please visit Hims & Hers H ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims related to deceptive practices in promoting and selling medications [1][2][3] Group 1: Lawsuit Details - The class action lawsuit, titled Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, for seeking lead plaintiff status [1][4] - Allegations include that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Following the termination of its partnership with Novo Nordisk due to these allegations, Hims & Hers' stock price dropped by over 34% [3] Group 2: Company Background - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk on April 29, 2025, which was later terminated due to the aforementioned allegations [2][3] Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and is recognized as a leading law firm in securities fraud and shareholder litigation [5] - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone, and has been ranked 1 in securing monetary relief for investors [5]

Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns during the specified Class Period [1][3]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [3]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [3]. - The positive statements made by the company regarding its business and operations were deemed materially misleading and lacked a reasonable basis [3]. Group 2: Legal Process and Participation - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [4]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the class [4]. - Investors can choose to participate actively or remain absent from the proceedings without affecting their ability to share in any recovery [4]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [5]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013, recovering hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the offerings of compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. - Allegations include misrepresentation of the partnership with Novo Nordisk, claiming compliance with FDA regulations regarding the sale of compounded semaglutide [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement on June 23, 2025, that it was terminating the partnership due to Hims & Hers' deceptive practices, the company's stock price fell by $22.24 per share, a decline of over 34% [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2] - It is alleged that this situation created a significant risk of termination of the collaboration between Hims and Novo Nordisk [2] - The defendants' positive statements regarding the company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing substantial recoveries for shareholders and has been recognized as a top securities litigation firm in the United States for seven consecutive years [4]

Core Viewpoint - Hims & Hers Health, Inc. is experiencing a surge in retail investor interest, positioning it as a potential candidate for the next "meme stock" rally due to high short interest and social media attention [1] Group 1: Short Interest - Over 65 million shares of Hims & Hers, accounting for approximately 33.5% of its public float, are sold short, indicating a high level of short interest that makes it a target for a potential short squeeze [2] - This elevated short interest is significantly above average, attracting retail traders who often coordinate on social media platforms [2] Group 2: Social Media Buzz - Discussions surrounding Hims & Hers stock have surged nearly 1,000% in the past month, making it the twelfth most-mentioned stock on WallStreetBets [3] - The attention from individual investors is attributed to the company's innovative approach and brand equity, as noted by a trading behavior analyst [4] Group 3: Growth Potential - Analysts project Hims & Hers to achieve an EPS growth of nearly 178% in the next year, indicating strong growth potential that retail investors are keen to capitalize on [5] - The company has reported a significant revenue increase of 111% year-over-year and an expansion of its user base to 2.4 million subscribers, differentiating it from typical meme stocks [6] Group 4: Market Sentiment - Retail-driven momentum for Hims & Hers is expected to continue as long as the company maintains its growth, innovation, and user experience, alongside interest from institutional and online investors [7] - As of the latest publication, shares of Hims & Hers Health were up 0.79% at $57.7 [8]

Group 1 - A bipartisan group of 81 lawmakers is pressuring the FDA to take action against counterfeit GLP-1 drugs and mixtures [1][2] - Hims & Hers Health Inc. (HIMS), a provider of affordable weight loss medications, experienced a short-term stock drop, declining by 2.56% during the day [3]